We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Serial Procalcitonin Measurements Utilized in Hospitalized Community-Acquired Pneumonia

By LabMedica International staff writers
Posted on 19 Mar 2020
Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system. CAP, the most common type of pneumonia, is a leading cause of illness and death worldwide. Its causes include bacteria, viruses, fungi and parasites.

To improve the prognosis of CAP patients, assessment of its severity is important for selecting appropriate antimicrobial agents and site of treatment, whether as an outpatient or in hospital, including a general ward or intensive care unit (ICU). Either CURB-65 or the Pneumonia Severity Index (PSI) is often used to assess the severity of pneumonia because they have been validated to correlate well with prognosis.

Scientists at the Kurashiki Central Hospital (Okayama, Japan) investigated the usefulness of serial procalcitonin (PCT) measurements for predicting the prognosis and treatment efficacy for hospitalized CAP patients. This prospective, multicenter, cohort study enrolled consecutive CAP patients who were hospitalized at 10 hospitals in western Japan from September 2013 to September 2016.

Sputum and blood for cultures and blood for measuring serum antibodies were collected on admission to detect the causative pathogens of CAP. In all hospitals, the serum PCT levels were measured by the Elecsys BRAHMS PCT automated immunoassay (Roche Diagnostics GmbH, Mannheim, Germany), which had a detection limit of 0.02 ng/mL.

The investigators reported that in the 710 patients, 366 microorganisms were identified. The most common causative microorganism was Streptococcus pneumoniae (22.2%), followed by Haemophilus influenzae (11.1%). Both PCT and CRP values on day 1 (D1), D3, and D7 were significantly higher in non-survivors than in survivors. From D1 to D3, the non-survivor group showed increased PCT (PCT D3/D1 > 1) more often than the survivor group, whereas the increase of CRP (CRP D3/D1 >1) was not significantly different. Compared with patients with treatment success, patients with early treatment failure showed significantly higher values of PCT D1, D3, and CRP D3, but similar CRP D1 values.

The authors concluded that to assess prognosis and treatment efficacy in CAP, it would be ideal to measure PCT serially, not only on admission, but again on day 3. If the values of PCT increase from admission to day 3, the antibiotics may need to be changed, or the patients who have deteriorated may require close monitoring. The study was published on March 1, 2020 in the International Journal of Infectious Diseases.

Related Links:
Kurashiki Central Hospital
Roche Diagnostics GmbH



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Respiratory QC Panel
Assayed Respiratory Control Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.